Acute interstitial nephritis related to immune checkpoint inhibitors

Julie Belliere,Nicolas Meyer,Julien Mazieres,Sylvie Ollier,Serge Boulinguez,Audrey Delas,David Ribes,Stanislas Faguer
DOI: https://doi.org/10.1038/bjc.2016.358
IF: 9.075
2016-11-10
British Journal of Cancer
Abstract:Background:Immune checkpoint inhibitors (anti-PD1 or anti-CTLA-4) are increasingly used in various cancers. Immune checkpoint inhibitors (ICI)-related renal disorders are poorly described (9 cases) and were only related to Ipilimumab.Methods:Retrospective collection of clinical charts of all the patients admitted for renal disorders following ICI in the University Hospital of Toulouse (France).Results:We report on adverse renal events that occurred in three patients treated with anti-PD1 (nivolumab or pembrolizumab) or anti-CTLA-4 (ipilimumab). Acute kidney injury occurred at 4–12 weeks after initiation of treatment, and harbored features of tubulo-interstitial nephritis (interstitial polymorphic inflammatory infiltrate with predominant CD3+ CD4+ T cells, associated with granuloma in one). Following withdrawal of ICI and steroid intake, estimated glomerular-filtration rate had improved in all patients.Conclusions:These data suggest that all ICI can lead to acute interstitial nephritis, possibly related to the presence of autoreactive clonal T cells. We recommend that patients receiving ICI should undergo renal monitoring every 2 weeks for 3–6 months.
oncology
What problem does this paper attempt to address?